Company Launches #INKEDforALS Campaign in its Commitment to Raising Awareness for the ALS Community During ALS Awareness Month
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today is honored to support ALS Awareness Month 2020 with the launch of “#INKEDforALS”, a campaign that aims to raise awareness for ALS. The campaign will serve as a platform to bring people together to educate and encourage conversation about ALS and celebrate the efforts of the caregivers and physicians who are fighting alongside people with ALS.
In support of this year’s ALS Awareness Month, Amylyx created a temporary tattoo to raise awareness and funds, spark conversation about ALS and rally this resilient community together to help fight the disease. To help take action alongside this effort, Amylyx is encouraging the community to:
- Order a temporary tattoo from www.INKEDforALS.com
- Apply the tattoo
- Take a photo with their new temporary tattoo and upload it to the photo gallery on www.INKEDforALS.com
- Post the photo on social media (Twitter, Facebook and/or Instagram) using the hashtag #INKEDforALS and encourage others to join by ordering their own tattoos
As a thank you for elevating awareness of those who are fighting this life-changing disease, Amylyx will donate to Muscular Dystrophy Association (MDA), I AM ALS, The ALS Association, the Sean M. Healey & AMG Center for ALS at Mass General’s HEALEY ALS Platform Trial, and Compassionate Care ALS (CCALs). To learn more about ALS Awareness Month and other ways to support the ALS community, we encourage you to visit these websites.
“We are honored to support ALS Awareness Month this year through the #INKEDforALS campaign,” said Justin Klee, Co-CEO and Co-Founder of Amylyx. “Even when we are social distancing, we can still find ways to come together and unite in the fight against ALS, each day of the year.”
According to the latest statistics, people living with ALS spend approximately one-third (12 months) of their disease course searching for diagnosis.i,ii,iii,iv,v ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron degeneration in the brain and spinal cord. Motor neuron loss in ALS leads to the deterioration of muscle function, causing the loss of movement, speech, and breathing. Currently available therapies show limited impact on disease progression, leaving an unmet need for people with ALS.
“With social distancing in place, this year’s ALS Awareness Month is especially important to us,” said Joshua Cohen, Co-CEO, Chairman, and Co-Founder of Amylyx. “It is our hope through this campaign that we can raise additional awareness of ALS and inspire action and lasting conversations.”
At the end of 2019, Amylyx announced that AMX0035, an investigational therapy designed to reduce neuronal death and dysfunction, met its clinical endpoint in the CENTAUR study in people with ALS (NCT03127514). In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05), the primary outcome of the trial. Detailed and published results from this study are expected shortly. The trial also assessed the safety and tolerability of AMX0035 and its effect on other measures that are critical to people with ALS.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.
i Paganoni S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5-6):453-456. 2. 34. 5
ii Traxinger K, et al. Neurol Clin Pract. 2013; 3(4):313-320.
iii Turner MR, et al. J Neurol Sci. 2010;294(1-2):81-85.
iv Jordan H, et al. Muscle Nerve. 2015;51(6): 815-821.
v Galvin M, et al. BMJ Open. 2017;7(3):e014985.
Source: Amylyx Pharmaceuticals, Inc.